OncoDNA: Winner of the Healthcare and Life Science category of Deloitte’s 2018 Technology Fast 50 competition.
OncoDNA, the healthcare technology company making precision medicine a reality announced having been awarded yesterday by Deloitte’s Belgium for the 2018 Fast 50 winner price in the healthcare category.
Deloitte Belgium released yesterday evening its 2018 Technology Fast 50 winners from the fifty fastest-growing technology companies in Belgium. This award recognizes the fastest growing ones in terms of percentage of growth in turnover over the past four years.
This price comes 3 years after OncoDNA having been awarded by Deloitte Belgium as the Belgian Healthcare Rising Star’s Most Disruptive Innovator.
Nikolaas Tahon, Managing Partner Deloitte Private said “While the awards and celebrating the achievements of the Fast 50 participants is important, Deloitte’s Technology Fast 50 is more than a competition. Our aim is to build a community and offer all of its members the opportunity to build their network, share best practices and deepen their knowledge of business-critical topics. Since its launch in 2016, the Fast 50 Business Forum has proven to be an important element of the programme. This year around 230 tech companies, Fast 50 partners and representatives from the world of innovation, technology and investment attended the event to share experiences and prepare for growth opportunities.”
The 2018 Belgian Deloitte Technology Fast 50 competition was organised in association with Oracle/Netsuite and Fortino Capital. For more information, visit www.fast50.be.
OncoDNA’s technology adoption has been the last weeks highly confirmed by many initiatives like Luxembourg’s national funding for OncoDNA’s Cancer Molecular Profiling and reimbursement by the first Belgian mutuality for stage III and IV cancers in second line.
Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: “We are proud of the great award and having been recognized as a major Belgian healthcare technology company for the second time by Deloitte since our foundation in 2012. We are only at the beginning of story as the company reached new important pharmaco-economic milestones with starting of funding of our tumor profiling solution by private and public insurers.
Recently a fundraising process have been started by OncoDNA with the admission to give the company additional sales and marketing power and position OncoDNA as the European Molecular Profiling Champion in the next years.
About DELOITTE Belgium :
value added services in audit, accounting, tax and legal, consulting and financial advisory services.
In Belgium, Deloitte has more than 4,000 employees in 12 locations across the country, serving national and international companies, from small and middle-sized enterprises, to public sector and non-profit
organisations. The turnover reached 510 million euros in the financial year 2018.
Deloitte Belgium CVBA is the Belgian affiliate of Deloitte NWE LLP, a member firm of Deloitte Touche
Tohmatsu Limited. We are focused on client service through a global strategy executed locally in more than 150 countries. With access to the deep intellectual capital in the region of 286.000 people worldwide, our member firms (including their affiliates) deliver services in various professional areas covering audit, tax, consulting, and financial advisory services. Our member firms serve over one-half of the world’s largest companies, as well as large national enterprises, public institutions, and successful, fast-growing global companies. In 2018, DTTL's turnover reached over $43.2 billion.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by
guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche
Tohmatsu Limited and its member firms.
About OncoDNA :
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ that continuously ‘learns’ from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to an individual patient’s cancer profile. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, and employs c. 55 employees in four countries. For more information please visit www.oncodna.com
|OncoDNA||+32 (0) 71 18 35 00|
|Jean-Pol Detiffe, CEO|